Document Detail


Carnitine-related alterations in patients with intermittent claudication: indication for a focused carnitine therapy.
MedLine Citation:
PMID:  8653874     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Carnitine metabolism is altered in peripheral arterial disease. L-carnitine supplementation may correct these alterations and improve walking performance. METHODS AND RESULTS: Plasma levels of carnitine and its esters were measured at rest and after maximally tolerated exercise in 22 claudicant patients and 8 normal subjects. One week later, this protocol was repeated in patients after random administration of placebo or L-carnitine (500 mg IV as a single bolus). Two groups of patients emerged. In 10 patients (group IC1), the plasma level of acetylcarnitine at rest was 3.7 +/- 0.2 micromol/L and increased significantly (P<.01) at maximally tolerated exercise. In 12 patients (group IC2), the resting level of plasma acetylcarnitine was elevated (7.9 +/- 0.7 micromol/L, P<.01) and decreased with exercise. Furthermore, group IC2 patients had a significantly lower walking capacity than group IC1 patients. In both groups, placebo did not affect the metabolic profile, nor did it improve exercise performance. Conversely, after L-carnitine administration, all but one patient in group IC2 (n=7) showed an increase in plasma acetylcarnitine concentration during exercise versus the decrease observed without L-carnitine. This metabolic effect was accompanied by a significant increase (P<.01) in walking capacity. Interestingly, in group IC1 patients (n=5), L-carnitine neither improved walking capacity nor modified the metabolic profile. Statistical analysis showed that changes in walking capacity with L-carnitine treatment were influenced exclusively by exercise-induced changes in plasma acetylcarnitine. CONCLUSIONS: In patients with intermittent claudication, assessment of plasma acetylcarnitine at rest and after exercise may be a means to select a target population for L-carnitine therapy.
Authors:
G Brevetti; F di Lisa; S Perna; R Menabó; R Barbato; V D Martone; N Siliprandi
Related Documents :
9021624 - Noninvasive quantification of muscle oxygen in subjects with and without claudication.
663544 - Effects of physical training in intermittent claudication.
7369534 - Fibrositic myofascial pain in intermittent claudication: significance of trigger areas ...
1679624 - Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects w...
24967004 - Xanthine oxidase activity is associated with risk factors for cardiovascular disease an...
19890484 - If you want patients with knee osteoarthritis (oa) to exercise: tell them about nsaids.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Circulation     Volume:  93     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1996 May 
Date Detail:
Created Date:  1996-07-26     Completed Date:  1996-07-26     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1685-9     Citation Subset:  AIM; IM    
Affiliation:
Department of Medicine, University Federico II, Naples, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetylcarnitine / blood
Carnitine / blood*,  therapeutic use
Exercise
Humans
Intermittent Claudication / blood*,  drug therapy
Male
Middle Aged
Rest
Chemical
Reg. No./Substance:
14992-62-2/Acetylcarnitine; 541-15-1/Carnitine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mean red cell volume as a correlate of blood pressure.
Next Document:  Electrophysiological mechanisms in successful radiofrequency catheter modification of atrioventricul...